Tafenoquine

Drug Profile

Tafenoquine

Alternative Names: 60P 003; Etaquine; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine succinate; UNII-DL5J0B8VSS; WR 238605; WR 238605 succinate

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer 60 Degrees Pharmaceuticals; GlaxoSmithKline; Medicines for Malaria Venture; Walter Reed Army Institute of Research
  • Class Aminoquinolines; Antimalarials; Antiprotozoals; Small molecules
  • Mechanism of Action Apoptosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malaria
  • Discontinued Babesiosis; Pneumocystis pneumonia

Most Recent Events

  • 06 Feb 2017 Phase-II clinical trials in Malaria (Combination therapy, In children, In infants, In adolescents) in Vietnam (PO) (NCT02563496)
  • 01 Feb 2017 Phase-I clinical trials in Malaria (Prevention; In volunteers) in Australia (PO) (ACTRN12617000102370)
  • 18 Jan 2017 60 Degrees Pharmaceuticals plans a phase I trial in Malaria (Prevention) in Australia (ACTRN12617000102370)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top